Compare PCRX & GDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | GDRX |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 919.9M |
| IPO Year | 2011 | 2020 |
| Metric | PCRX | GDRX |
|---|---|---|
| Price | $26.12 | $2.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $32.86 | $5.07 |
| AVG Volume (30 Days) | 885.6K | ★ 2.1M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | 0.09 |
| Revenue | $716,791,000.00 | ★ $800,651,000.00 |
| Revenue This Year | $6.24 | $2.35 |
| Revenue Next Year | $9.53 | $2.90 |
| P/E Ratio | $55.17 | ★ $32.95 |
| Revenue Growth | ★ 3.14 | 1.30 |
| 52 Week Low | $18.18 | $2.61 |
| 52 Week High | $27.64 | $5.81 |
| Indicator | PCRX | GDRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.85 | 46.93 |
| Support Level | $24.20 | $2.67 |
| Resistance Level | $26.48 | $2.79 |
| Average True Range (ATR) | 0.98 | 0.08 |
| MACD | -0.11 | 0.03 |
| Stochastic Oscillator | 68.10 | 44.00 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.